Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPreventive Services & ScreeningAetna meningococcal vaccine Coverage Policy Update…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0356

    Meningococcal Vaccines

    Customize your policy alerts

    Sign up for Aetna Policy 0356 alerts

    Get alerted when Policy 0356 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity coverage for meningococcal conjugate (MenACWY) and serogroup B (MenB) vaccines according to CDC ACIP recommendations, and lists indications, booster schedules, coding, and investigational exclusions relevant to members and providers.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyMeningococcal Vaccines
    Policy CodePolicy 0356
    Change TypeNo material change
    Effective DateNov 23, 1999
    Last ReviewFeb 15, 2024
    Next Review DateApr 11, 2024
    Key ActionFollow ACIP recommendations: administer MenACWY routinely at 11–12 years with a booster at 16 years and use MenB per shared clinical decision-making or for increased-risk persons.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2vaccine classes covered
    11-18 yrsroutine adolescent MenACWY age range
    375US cases cited (2019)
    15%case-fatality ratio
    every 5 yrsMenACWY booster interval
    04/11/2024policy next review

    Coverage Criteria for Meningococcal Vaccines

    MenACWY (conjugate) vaccine - Routine and risk-based coverage

    Covered when following ACIP recommendations are met

    Routine adolescent vaccination: Single dose at age 11 or 12 years followed by a booster dose at age 16 years; adolescents who receive first dose at 13–15 years should receive booster at 16–18 years (minimum interval 8 weeks); first dose after 16th birthday generally does not require booster unless increased risk for meningococcal disease.age-based and interval rules per ACIP

    References chunks 3,16,17

    MenACWY - Increased risk indications and booster schedules

    Covered for members aged 2 months and older with listed risk factors; booster intervals depend on age and indication

    Risk indications: Member has one or more of: anatomic or functional asplenia (including sickle cell disease); persistent complement component deficiencies or use of complement inhibitors (e.g., eculizumab, ravulizumab); HIV infection; exposure during an outbreak; travel to hyperendemic/epidemic areas; microbiologist routinely exposed to N. meningitidis isolates; military recruit; unvaccinated or undervaccinated first-year college students living in residence halls.age >= 2 months

    See chunks 3,4,16

    Booster timing for ongoing risk: If ongoing risk: age 2–6 years — single booster dose 3 years after primary vaccination and every 5 years thereafter; age >=7 years — single booster dose 5 years after primary vaccination and every 5 years thereafter; microbiologists — single dose 5 years after primary and every 5 years; military recruits — every 5 years based on assignment.depends on age and risk

    See chunks 4,18

    Booster during outbreak: If identified as at increased risk during outbreak: age 2–6 years — single dose if >=3 years since prior vaccination; age >=7 years — single dose if >=5 years since prior vaccination.time since prior vaccination

    See chunk 4

    MenB (serogroup B) vaccine - Risk-based and shared decision-making coverage

    Covered when ACIP recommendations are met

    MenB at increased risk: For persons >=10 years with one or more of: anatomic or functional asplenia; persistent complement component deficiencies or use of complement inhibitors; exposure during a serogroup B outbreak; microbiologists routinely exposed to N. meningitidis isolates. Dosing schedule varies by vaccine brand. Booster: single dose 1 year after completion of primary series, then every 2–3 years if ongoing risk.age >= 10 years

    See chunk 5,22

    MenB shared clinical decision-making: Vaccination of adolescents and young adults aged 16 to 23 years with a 2-dose MenB series may be considered based on shared clinical decision-making (preferred age 16–18 years). Booster doses are not routinely recommended unless the person becomes at increased risk.age 16–23 years

    See chunks 20,21

    ACIP/FDA Indications and Dosing

    Covered when ACIP-recommended indications and labeled age ranges/dosing are met:

    Adolescent routine MenACWY: Adolescents: routine MenACWY dosing per ACIP — single dose at age 11 or 12 and booster at age 16 if first dose before 16th birthday; persons aged 19–21 who have not received a dose after their 16th birthday may receive a single catch-up MenACWY dose.ages 11–21 per ACIP guidance; booster at 16 if indicated

    See chunks 18,17

    MenACWY high-risk periodic boosters: Persons >=2 years with persistent complement deficiencies, asplenia, or HIV: booster intervals depend on age — ages 2–6: single booster >=3 years after primary and every 5 years thereafter; ages >=7: single booster 5 years after primary and every 5 years thereafter.3 years (ages 2–6) or 5 years (>=7) after primary; repeat every 5 years

    See chunks 4,18

    MenACWY microbiologists/travelers/outbreaks: Microbiologists and persons traveling to hyperendemic/epidemic areas: single booster 5 years after primary and every 5 years thereafter; during outbreaks, younger age intervals apply (>=3 years for ages 2–6; >=5 years for age >=7).

    Experimental and investigational (Not covered)

    The following are considered experimental and investigational

    Not covered - experimental: Meningococcal vaccine for indications not listed in Section I of this policy; use of saliva testing of antibody levels against meningococcal serogroups for monitoring meningococcal vaccine responses.indication-based

    See chunk 6

    Some member benefit plans exclude coverage of immunizations for travel or work. Verify the member's benefit plan description before administering or billing for meningococcal vaccines intended primarily for travel or occupational requirements.

    Administration of meningococcal vaccines or booster doses outside FDA‑licensed age ranges (for example, MenB products administered to persons >25 years or MenACWY boosters given outside the ages specified on product labeling) is considered off‑label. Such off‑label use should be clinically justified and documented when submitted for coverage review.

    Salivary antibody thresholds reported in the cited study were derived from samples collected only in children aged 10 to 15 years. Because these thresholds were not established in broader age groups, they require validation in larger, age‑diverse studies before being generalized to other populations.

    Use of saliva testing to measure meningococcal polysaccharide‑specific antibody levels for monitoring vaccine responses is listed as experimental and investigational and is not considered medically necessary because effectiveness and generalizability have not been established.

    Routine MenB vaccination is not recommended for all adolescents. ACIP advises that a 2‑dose MenB series for persons aged 16 to 23 years may be given based on shared clinical decision‑making, with the preferred age being 16–18 years. Booster doses are not routinely recommended unless the individual later meets criteria for increased risk.

    Billing and Coding

    Covered CPT Codes (if selection criteria met)CPTCovered
    90619Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use.
    90620Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B, 2 dose schedule, for intramuscular use.
    90621Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use.
    90623Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use.
    90644Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use.
    90733Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use.
    90734Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MenACWY), for intramuscular use.
    90471Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vacctine/toxoid).
    Related HCPCS/J-codes referencedHCPCS
    J0596Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units.
    J0597Injection, C-1 esterase inhibitor (human), berinert, 10 units.
    J0598Injection, C1 esterase inhibitor (human) cinryze, 10 units.
    J1300Injection, eculizumab, 10 mg.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    B20Human immunodeficiency virus [HIV] disease.
    D57.00 - D57.819Sickle-cell disorders.
    D84.1Defects in the complement system.
    D89.89Other specified disorders involving the immune mechanism, not elsewhere classified.
    Q89.01Asplenia (congenital).
    Z20.811Contact with and (suspected) exposure to meningococcus.
    Z23Encounter for immunization.
    Z94.0Kidney transplant status.
    Z94.1Heart transplant status.
    Z94.2Lung transplant status.
    1–10 of 14
    1/2
    Codes not covered for indications listed in CPBICD-10Not Covered
    Z01.84Encounter for antibody response examination [monitoring meningococcal vaccine responses]
    Salivary IgG thresholds (ng/ml)
    MenC salivary IgG threshold≥3.54 ng/ml
    MenW salivary IgG threshold≥2.00 ng/ml
    MenY salivary IgG threshold≥1.82 ng/ml
    Serum correlate of protection
    Serum correlate of protection (rSBA)rSBA titer ≥128
    Assay type usedSerum bactericidal assay using rabbit complement (rSBA)

    Provider Actions, Documentation, and Billing Notes

    Prior Authorization

    Prior authorization / plan check

    The policy does not list any specific prior authorization requirements for meningococcal vaccines; check member benefit plan descriptions for exclusions (for example, some plans exclude immunizations for travel or work).

    • Verify member benefit plan for travel- or work-related immunization exclusions before billing.
    Prior Authorization

    Prior authorization — none specified

    No explicit prior authorization rules are stated in the policy excerpt; providers should follow product-labeled age indications when ordering vaccines (e.g., Menactra, Menveo, MenQuadfi, Bexsero, Trumenba).

    • Confirm age is within FDA-approved range for the selected vaccine prior to administration.
    Prior Authorization

    Background and Epidemiology

    Neisseria meningitidis is the cause of invasive meningococcal disease, which can lead to substantial morbidity and mortality. Although incidence in the United States has declined, adolescents and young adults remain an important risk group; ACIP provides routine and risk‑based recommendations for MenACWY and MenB vaccines, including age‑specific dosing and booster guidance to reduce the burden of invasive meningococcal disease.

    Definitions and Vaccine Names

    MenACWY
    DefinitionQuadrivalent meningococcal conjugate vaccines covering serogroups A, C, W, and Y
    ExamplesMenactra (MenACWY-D), Menveo (MenACWY-CRM), MenQuadfi (MenACWY-TT)
    Indication contextUsed for routine adolescent vaccination and for persons at increased risk per ACIP recommendations
    MenB
    DefinitionSerogroup B meningococcal vaccines
    ExamplesTrumenba (MenB-FHbp) and Bexsero (MenB-4C)
    Dosing noteDosing varies by brand (2- or 3-dose schedules); follow product labeling

    Policy Revision History

    2024-02-15last_reviewLatest

    Policy last reviewed on 2024-02-15.

    1999-11-23effective

    Policy originally became effective on 1999-11-23.

    2024-04-11next_review

    Next scheduled policy review on 2024-04-11.

    Policy Summary
    PayerAetna
    PolicyMeningococcal Vaccines
    Policy CodePolicy 0356
    Change TypeNo material change
    Effective DateNov 23, 1999
    Last ReviewFeb 15, 2024
    Next Review DateApr 11, 2024
    Key ActionFollow ACIP recommendations: administer MenACWY routinely at 11–12 years with a booster at 16 years and use MenB per shared clinical decision-making or for increased-risk persons.
    SourceLink
    On This Page
    Coverage Criteria for Meningococcal VaccinesBilling and CodingProvider Actions, Documentation, and Billing NotesBackground and EpidemiologyDefinitions and Vaccine NamesPolicy Revision History
    5 years standard; 3 years in younger children during outbreak

    See chunks 4,18

    MenB routine shared decision-making: For adolescents 16–23 years (preferred 16–18 years), MenB vaccination is based on shared clinical decision-making as a 2-dose series; not routinely recommended for all adolescents.ages 16–23 (preferred 16–18)

    See chunks 20,21

    MenB for increased-risk persons: Persons >=10 years with increased risk (asplenia, complement deficiency, complement inhibitor use, microbiologists, outbreak exposure): MenB primary series per product schedule and booster at 1 year after primary series completion, then every 2–3 years if remain at increased risk.boosters at 1 year then every 2–3 years if ongoing risk

    See chunks 5,22

    MenB dosing/product-specific rules: MenB products are not interchangeable; use the same product for all doses. If product unknown, restart series with a known product. If mixed products were given, an additional dose with the selected product is required to complete a valid series. Minimum interval of 4 weeks between any two repeated doses when repeating doses.minimum 4-week interval for repeated doses

    See chunk 21

    FDA-labeled product indications and booster labeling: Menactra: indicated 9 months–55 years (two-dose primary for 9–23 months; single dose for 2–55 years); Menveo: indicated 2 months–55 years; MenQuadfi: indicated >=2 years. MenACWY booster labeling: single dose for individuals 15–55 years at continued risk if >=4 years since prior dose (product labels vary). MenB (Bexsero, Trumenba): indicated 10–25 years; Trumenba may be given as 2- or 3-dose schedule per label; Bexsero is a 2-dose schedule.

    See chunks 25,30,31,33

    Use in study
    rSBA ≥128 was used as the correlate of protection for ROC analysis versus salivary IgG
    Acceptable AUC for salivary test
    Acceptable AUC thresholdAUC ≥0.80 considered adequate
    Best reported AUCAUC 0.95 for MenC
    Performance for MenW and MenYAUC >0.80 (adequate) reported for MenW and MenY

    Prior authorization

    The document contains no specified prior authorization requirements for these vaccines.

    Step Therapy

    Step therapy

    No step therapy requirements are specified in this policy excerpt.

    Step Therapy

    Use the same MenB product for the primary series

    For MenB, all doses in a primary series must be the same product; if the prior product is unknown, the series must be restarted with a known product.

    • If two different MenB products were already given, select one product and give an additional dose with that product to complete a valid series.
    • When repeating MenB doses, observe a minimum interval of 4 weeks between any two repeated doses.
    Documentation Required

    Document MenB product and dates when completing series

    Document vaccine product name and administration dates to support series validity and coverage determination.

    • If product unknown, restart MenB series and record product and dates.
    • If mixed MenB products were used, document selection of product used to complete the series and the additional dose given.
    Billing Rule

    Coding and claim submission

    Use the applicable CPT/HCPCS procedure codes and ICD-10 diagnosis codes when submitting claims as listed in the policy code tables.

    • Refer to the policy's CPT/HCPCS and ICD-10 code lists (e.g., 90619, 90620, 90621, 90734, 90471; and relevant ICD-10 covered codes) when billing.
    Documentation Required

    Series completion when MenB product unknown or mixed

    If a MenB dose was given but the vaccine product is unknown, restart the series with a known product; if mixed products were given, an additional dose with the selected product is required to complete a valid series.

    • When repeating doses, maintain a minimum 4-week interval between any two repeated doses.
    • Document the product selected for series completion and dates of all doses to verify series validity.
    Note

    Saliva and serum antibody testing methods reported

    Research studies measured salivary and serum meningococcal polysaccharide-specific IgG using a fluorescent-bead-based multiplex immunoassay and functional serum bactericidal assay (rSBA) to evaluate saliva as a potential surrogate of protection.

    • Thresholds and ROC analysis were used to compare salivary IgG with serum rSBA titers.
    Denial Risk

    Benefit plan exclusions may trigger denial

    Some plans exclude coverage of immunizations for travel or work; denial of coverage may result if the immunization is for travel- or occupation-related indications and the member's benefit plan excludes such coverage.

    • Check the member's benefit plan description before administering or billing for travel- or work-related immunizations.
    Denial Risk

    Off-label booster age risk — document rationale

    Booster doses administered outside FDA-licensed age ranges (for example, MenACWY boosters beyond labeled ages for some products or MenB administered above age 25) are considered off-label; document clinical rationale if performed.

    • Confirm FDA-approved age ranges for the specific product before administering booster doses and document justification for any off-label administration.
    Note

    Provider actions — none specified

    No additional provider actions are specified in these policy excerpts.

    Increased risk for meningococcal disease
    Included conditionsPersistent complement deficiencies (including complement inhibitor use)
    Included conditionsAnatomic or functional asplenia (including sickle cell disease)
    Included conditionsHIV infection; microbiologists routinely exposed to N. meningitidis; outbreak exposure; certain travel or occupational assignments
    rSBA titer 6128
    Assay definitionSerum bactericidal assay using rabbit complement (rSBA)
    Protective titerrSBA titer ≥128
    Role in researchUsed as the correlate of protection in ROC analysis comparing serum and salivary IgG
    Salivary IgG threshold
    ConceptProposed minimum concentration of meningococcal polysaccharide-specific IgG in saliva to discriminate protected vs unprotected individuals
    Reported thresholdsMenC ≥3.54 ng/ml; MenW ≥2.00 ng/ml; MenY ≥1.82 ng/ml
    LimitationsThresholds derived from children aged 10–15 years and need validation in broader, longitudinal studies